Trial Profile
A Phase I/II, Randomized, Single-Blind, Placebo-Controlled Escalating Double-Dose, Safety and Priming Potential Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; Montanide ISA-51 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors BiondVax Pharmaceuticals; Scinai Immunotherapeutics
- 30 Jul 2012 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov record.
- 17 Nov 2009 New trial record